Athira Pharma, Inc.ATHANASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-29.47%
↓ 305% below average
Average (26q)
14.35%
Historical baseline
Range
High:247.64%
Low:-54.09%
Volatility
2103.1%
High variability
| Period | Value |
|---|---|
| Q3 2025 | -29.47% |
| Q2 2025 | -14.90% |
| Q1 2025 | -54.09% |
| Q4 2024 | -47.72% |
| Q3 2024 | -18.21% |
| Q2 2024 | 4.37% |
| Q1 2024 | -11.34% |
| Q4 2023 | -12.95% |
| Q3 2023 | 25.85% |
| Q2 2023 | 1.51% |
| Q1 2023 | 39.75% |
| Q4 2022 | -10.19% |
| Q3 2022 | 14.61% |
| Q2 2022 | 2.37% |
| Q1 2022 | 14.60% |
| Q4 2021 | 17.85% |
| Q3 2021 | -10.95% |
| Q2 2021 | 61.50% |
| Q1 2021 | 43.53% |
| Q4 2020 | -11.03% |
| Q3 2020 | 247.64% |
| Q2 2020 | 183.28% |
| Q1 2020 | -10.03% |
| Q4 2019 | -35.87% |
| Q3 2019 | -2.75% |
| Q2 2019 | 0.00% |
| Q1 2019 | 0.00% |